Project Grant W81XWH0710054

This $429,000 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will support research to uncover the structural and molecular mechanisms underlying calcium (Ca2+) signaling at contact sites between the endoplasmic reticulum (ER) and mitochondria in neurons. The research aims to utilize cutting-edge cryogenic electron tomography techniques to...

This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...

This $764,659 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research to investigate the mechanisms underlying neuropathic spontaneous pain. The key objectives are to characterize the role of local vascular movement in triggering neuropathic spontaneous pain, determine how mechanoreceptors in sensory neurons contribute...

The National Institute of Mental Health (NIMH) awarded a 3-year, $413,681 Project Grant (CFDA 93.242 - Mental Health Research Grants) to the University of Dayton Research Institute to study the role of phospholamban (PLN), a critical calcium regulatory protein, in the thalamic reticular nucleus (TRN) of the brain. The research aims to decipher the cellular and molecular mechanisms by which PLN regulates the signaling properties of TRN neurons and influences behavioral outcomes like locomotor...

Summary Under this $1.99M Cooperative Agreement awarded by the National Institute of Neurological Disorders and Stroke (NINDS) through the Drug Use and Addiction Research Programs (CFDA 93.279), Quiver Bioscience Inc. is developing antisense oligonucleotide (ASO) therapeutics targeting Nav1.7 voltage-gated sodium channels for the treatment of chronic neuropathic pain conditions, including erythromelalgia and small fiber neuropathy. The award, effective April 24, 2026 through March 31, 2028,...

Artery Therapeutics, Inc. received a $2.64M Cooperative Agreement from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded February 15, 2026, with completion targeted for March 15, 2028. The award funds two sequential clinical studies of CS6253, an ABCA1 (ATP-Binding-Cassette-Transporter A1) agonist in development for hereditary apolipoprotein E4 (APOE4)-associated dementia. Artery Therapeutics will conduct a subcutaneous (SC) injection pharmacokinetic...

This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $429,000.00 in funding to Thomas Jefferson University to conduct research on cell-type specific analysis of Src kinase-NMDA receptor complexes in schizophrenia. The goal of this 2-year project is to determine how Src kinase-mediated NMDA receptor signaling alterations are distinctly manifested in pyramidal neurons versus interneurons in the...

This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is focused on developing a novel drug candidate to treat demyelinating neuropathies. The $352,073 award will support rigorous in vivo testing of the experimental ABCA1 agonist drug, CS6253, in validated mouse models of hereditary peripheral nerve disorders characterized by impaired...

Novelmed Therapeutics, Inc. was awarded a $900,000 Project Grant from the National Institutes of Health's National Institute on Aging to develop a selective inhibitor of the alternative pathway of complement as a treatment for Neuromyelitis Optica Spectrum Disorder. Under the grant, Novelmed will conduct preclinical studies to evaluate its lead drug candidate NM5072, including in vitro and ex vivo assays to confirm the drug's mechanism of action and selective inhibition of the alternative...